SOBI North America Is Shopping For Growth
Executive Summary
Affiliate of the Swedish rare disease specialist has a goal to build the North American business to account for 50% of global sales, an effort that will involve organic growth and M&A.
You may also be interested in...
Sobi On The Look-Out For Licensing, M&A Opportunities
Swedish Orphan Biovitrum AB may be in a launch phase with first sales of its long-acting hemophilia products in Europe, but the company is already looking ahead to use its growing commercial capabilities for other products.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.